Ko, Jina
Wilkovitsch, Martin http://orcid.org/0000-0002-6809-6972
Oh, Juhyun
Kohler, Rainer H. http://orcid.org/0000-0001-6269-6590
Bolli, Evangelia
Pittet, Mikael J. http://orcid.org/0000-0002-2060-4691
Vinegoni, Claudio http://orcid.org/0000-0002-9818-3639
Sykes, David B. http://orcid.org/0000-0002-9788-0221
Mikula, Hannes http://orcid.org/0000-0002-9218-9722
Weissleder, Ralph http://orcid.org/0000-0003-0828-4143
Carlson, Jonathan C. T. http://orcid.org/0000-0003-4139-9057
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K99CA256353, R01CA206890, R01CA257623, UH3CA202637, R01CA206890, P01CA069246, U01CA206997)
CSB Development Fund
Article History
Received: 1 October 2021
Accepted: 28 April 2022
First Online: 2 June 2022
Competing interests
: The authors declare the following competing interests. J.C.T.C., R.W. and H.M. declare the filing of a patent (PCT/US2021/053439, pending; Bioorthogonal linkers and reactions), which was assigned to Massachusetts General Hospital. R.W. is a consultant to ModeRNA, Tarveda Therapeutics, Lumicell, Seer, Earli, Aikili Biosystems and Accure Health, consultancies that are unrelated to the subject matter of this work.